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ORIGINAL INVESTIGATION
Effects of background statin therapy 
on glycemic response and cardiovascular events 
following initiation of insulin therapy in type 2 
diabetes: a large UK cohort study
Uchenna Anyanwagu, Jil Mamza, Richard Donnelly and Iskandar Idris*
Abstract 
Aim: Statins may increase the risk of new-onset diabetes and adversely affect glycaemic control, but their effects on 
the glycemic response and mortality outcomes following commencement of insulin therapy in patients with Type 2 
Diabetes (T2D) are unclear.
Methods: A retrospective cohort study was conducted in 12,725 insulin initiators with T2D using The Health 
Improvement Network (THIN) UK database. Changes in HbA1c at 6, 12, 24 and 36 months, and the 5-year risk of mor-
tality and (3-point) major adverse cardiovascular events (MACE), were compared between prior users (n = 10,682) and 
non-users (n = 2043) of statin therapy who were newly commenced on insulin treatment. Cox proportional hazard 
models were used to estimate the hazard ratios of the different outcomes.
Results: Mean age of the cohort was 58.7 ± 14.0 years (51% male) and mean baseline HbA1c was 8.7 ± 1.8%. A 
greater initial reduction in HbA1c was observed following insulin initiation in the non-users of statins compared with 
the users, which was significant in the short term (−0.34% vs −0.26% at 6 months; mean diff = −0.09%, p = 0.004) 
but not in the long term: −0.31% versus −0.35% at 3 years (mean diff = 0.05%, p = 0.344). CV events (3-point MACE) 
were 878 versus 217 in statin users versus non-users (20.7 vs 30.9 per 1000 person-years; adjusted Hazard Ratio (aHR) 
1.36 (95% CI 1.15–1.62; p < 0.0001). In a subgroup analysis of individual statins, HbA1c was higher throughout the 
study duration with all statins relative to non-users of statin therapy (p < 0.05). The aHRs for 3-point MACE for atorvas-
tatin, simvastatin, rosuvastatin and pravastatin were 0.82 (95% CI 0.68–0.98), 0.67 (0.55–0.82), 0.56 (0.39–0.81) and 0.78 
(0.60–1.01), respectively.
Conclusions: Following initiation of insulin therapy in patients with T2D in routine care, concurrent use of a statin 
was associated with less good glycaemic control in the short-term but a much lower risk of major adverse CV events.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Evidence from randomized controlled trials shows that 
statin therapy reduces the risk of fatal and nonfatal car-
diovascular (CV) events in patients with T2D [1–3]. 
Thus, clinical guidelines advocate their routine use in all 
patients with diabetes aged 40-75 years, and in younger 
patients with high CV risk [4, 5].
Various studies have shown that statins may also have 
modest adverse effects on glucose and insulin metabo-
lism, e.g. increasing the risk of new-onset diabetes, espe-
cially in higher doses and with the more potent statins 
[6–9], but the relationship between statin use and gly-
caemic control in patients with established T2D is much 
less clear. Previous studies have reported an increase 
in HbA1c [10, 11] while others have reported either no 
effect or a reduction in glucose levels [12–14]. A meta-
analysis of 9 randomized controlled trials (RCTs) involv-
ing 9696 participants reported that glycaemic control was 
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adversely affected among those patients randomized to a 
statin compared with placebo, and that statin treatment 
also increased HbA1c in those patients with established 
T2D [15]. None of these studies, however, has specifi-
cally focused on T2D patients who are commencing 
insulin therapy, nor have they excluded the possibility of 
bias due to differential attrition rates and/or differential 
adjustment of other glucose-lowering therapies (GLTs) 
between the statin and control groups [16].
More information is certainly needed about the asso-
ciations between statin use, glycaemic control and CV 
risk specifically in the insulin-treated T2D population, 
because these patients tend to have more complications, 
higher absolute CV risk and a longer duration of diabe-
tes. Commencing insulin can also affect lipid levels and 
overall CV risk [17]. Thus, in routine practice some of the 
well-recognised clinical inertia may be due to uncertainty 
about the optimal timing and the overall risk–benefit 
balance of insulin initiation in these patients. For exam-
ple, it was reported that primary prevention with statins 
was initiated in less than half of diabetic patients after a 
first MI, despite the presence of one or more markers of 
very high cardiovascular risk in nearly all [18]. Therefore, 
the aim of this large cohort study was to investigate the 
effects of background statin use on glycaemic control 
and CV outcomes following commencement of insulin 
therapy in patients with T2D in a routine primary care 
setting.
Methods
Study design
This was a retrospective cohort study using a UK primary 
care database.
The Health Improvement Network (THIN) Database
THIN is a large UK electronic Primary Care database 
with longitudinal records obtained from approximately 
587 General Practices. It contains details of over 12.4 
million patients, of which 3.61 million were active as of 
January 2014. Trained doctors and specialist nurses sys-
tematically enter routine clinical information into this 
database. This includes specialist or Primary care con-
sultations, diagnoses, laboratory results, prescriptions, 
referrals, hospital admissions, immunisations and impor-
tant clinical measures such as body weight, height and 
body mass index (BMI). Information on the patients’ 
demography, lifestyle characteristics (e.g. alcohol use 
and smoking), socio-economic status (Townsend depri-
vation scores), ethnicity, religion and languages are also 
included. Several studies have validated the THIN data-
base and shown it to be demographically representative 
of the wider UK population in terms of demography, 
disease prevalence and mortality [19]. Our own group 
and others have also used the THIN database to evalu-
ate diabetes-related outcomes in routine clinical practice 
[20, 21].
Ethical approval for this study was obtained from the 
South-East Research Ethics Committee.
Study participants
We obtained data on 12,725 people in the THIN database 
who had a diagnosis of T2D, were >18 years of age and 
who initiated insulin therapy between December 2006 
and May 2014. Patients with type 1 or gestational diabe-
tes, or other forms of diabetes, and those with no con-
tinuous regular prescriptions for insulin in their records 
were excluded. For analysis of our secondary objective, 
we excluded patients with a history of CV disease before 
or 180 days after initiating insulin.
Follow‑up and endpoints
We followed-up all insulin-initiators from the point they 
commenced statin treatment and compared them with 
those who did not commence statins until the first inci-
dent of any of the secondary outcomes: 3-point major 
adverse cardiovascular events (MACE: all-cause mor-
tality or non-fatal myocardial infarction or stroke); loss 
to follow-up; discontinuation of insulin and/or statin 
therapy; or at the end of the 5-year follow-up period. 
Similarly, their baseline HbA1c, body weight and blood 
pressure were measured at baseline and at different time 
points after starting insulin (6, 12, 24 and 36 months).
The primary endpoints were glycaemic control (meas-
ured by change in HbA1c), changes in body weight, sys-
tolic blood pressure (SBP) and diastolic blood pressure 
(DBP) from baseline to 6, 12, 24 and 36  months after 
commencement of insulin treatment. These differences 
were computed and compared between the two treat-
ment groups (statin users versus non-users). The second-
ary endpoint was the time to the risk of a 3-point MACE. 
These outcomes were identified by their appropriate 
Read Codes in the database.
Baseline and endpoint characteristics
To adjust for the confounding effects some differences in 
baseline characteristics may have on the study outcomes, 
we extracted data on important clinical covariates. These 
included demographic variables such as age, gender, soci-
oeconomic status, alcohol and smoking status; impor-
tant clinical measures such as body weight, height, SBP 
and DBP; biochemical parameters, e.g. baseline HbA1c, 
serum creatinine, lipid-profile, use of other medications 
including other glucose-lowering therapies (GLTs); as 
well as comorbidity status, duration of diabetes treat-
ment, and duration of insulin use. These were included in 
our univariate analysis models from which the significant 
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covariates (those which had a significant association with 
both the exposure and outcomes) were added to the final 
Cox and linear regression models.
Statistical analysis
We computed summary data for the mean, standard 
deviations and proportions of the baseline characteristics 
and used Pearson’s Chi squared test and t test to deter-
mine the differences between the treatment groups at 
baseline.
For the missing values in HbA1c, weight, SBP and DBP 
at baseline and all the study time points, we observed 
that a small proportion of values for these covariates 
were completely missing at random. These missing values 
were then computed using multiple imputations using 
the chained equation (MICE) model. Thereafter, linear 
regression models were used to compute the mean dif-
ferences between baseline HbA1c, weight, SBP and DBP 
and the 6, 12, 24 and 36  month measurements respec-
tively while adjusting for significant baseline covariates.
For the secondary endpoints of MACE, we used a Cox 
proportional hazard model to estimate the marginal and 
adjusted hazard ratios (HRs) with 95% confidence inter-
vals, comparing the outcomes in the statin treated group 
to the non-user group. Furthermore, the crude and 
adjusted Kaplan–Meier estimates of survival functions 
between the two treatment groups were computed and the 
log-rank test was used to compare the equality of the sur-
vival curves between them. The absolute reduction in the 
probability of the incidence of MACE within the 5-year 
follow-up was computed from these survival functions.
Finally, we tested for any violation of the proportional 
hazard assumption of the Cox regression model, first by 
adding an interaction term of the predictor; secondly by 
log-minus-log survival curves; and thirdly by Schoenfeld 
residuals tests.
Subgroup analysis
We also performed a subgroup analysis to explore the 
individual statins (atorvastatin, simvastatin, rosuvastatin 
and pravastatin) identified in the database. The primary 
and secondary endpoints were determined in these indi-
vidual statin groups compared to the non-statin user 
group.
In all the analyses, we computed the point estimates 
with 95% confidence intervals (CI) at the conventional 
statistical significance level of 0.05. All analyses were 
conducted using Stata Software, version 14.
Results
Patient characteristics, cases and total follow up
A total of 12,725 new insulin users with T2D (mean age 
58.6  ±  14 years) were selected (Fig.  1). Among these 
83.9% were statin users. Mean follow up was 3.9 ±  1.5 
years, which represents a total follow-up of 49,516 per-
son-years. Table  1 shows the baseline characteristics of 
the treatment groups. Non-users of statins were signifi-
cantly younger, more likely to be female and had a sig-
nificantly shorter duration of diabetes and insulin use. 
Baseline HbA1c, body weight and DBP were similar in 
the two groups (Table  1). SBP was higher in the statin 
users.
Primary endpoints: metabolic outcomes
Association between prior statin use and glycaemic response
Glycaemic response was defined by the changes from 
baseline in HbA1c at 6, 12, 24 and 36  months after 
initiating insulin therapy. Figure  2a, b show the mean 
reductions in HbA1c and the mean HbA1c levels, 
respectively, at each of these time points. Both treat-
ment groups (statin users and non-users) showed a 
significant reduction in HbA1c throughout the dura-
tion of the study (Fig. 2b) but insulin therapy resulted 
in a greater reduction in HbA1c among non-users of 
statins (Fig. 2a). This was significant at 6 months with 
mean reductions of −0.26% versus −0.34% (mean 
diff 0.09%; 95% CI 0.03–0.15; p =  0.004) in the statin 
user versus non-user groups respectively, but not at 
36 months (corresponding mean reductions of −0.31% 
versus −0.35%; mean diff 0.05%; 95% CI −0.04 to 0.14; 
p = 0.172).
Relationship between statin use and other clinical 
measurements
There were increases in body weight following insu-
lin initiation but no significant differences between 
the 2 groups from 6 to 24  months (Additional file  2). 
At 36  months, however, statin users showed a small 
reduction in weight of 0.18  kg (p  =  0.031) versus 
an increase of 0.26  kg (p  =  0.405) in the non-statin 
group (mean diff  =  −0.54  kg, 95% CI −0.35 to 0.88; 
p = 0.099).
SBP decreased in both treatment groups throughout 
the study, but more so in non-users of statins (Addi-
tional file  1) with a significant difference at 6  months 
(−1.27 vs −1.86  mmHg; p  =  0.004) and 12  months 
(−1.5 vs −2.3  mmHg; p  =  0.021). These differences 
were not maintained at 24 months (−1.6 vs −2.4 mmHg; 
p  =  0.787) and 36  months (−2.4 vs −3.1  mmHg; 
p = 0.344). There was also a significant reduction in DBP 
in both treatment groups. Throughout the study, DBP 
was non-significantly lower among statin users com-
pared to non-users. For example, the respective changes 
in DBP ranged from 0.74 versus 0.59 mmHg at 6 months 
to 2.0 versus 1.44  mmHg at 36  months (Additional 
file 1).
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Secondary endpoints: risk of major adverse cardiovascular 
events (3‑point MACE)
Crude event rates
The probability of survival for the 3-point composite out-
come of all-cause mortality, non-fatal MI and stroke was 
significantly different between the statin user versus non-
user groups at 1-year (98.8% vs 99.2%) and 5-years (89.9% 
vs 84.7%) of follow-up (log-rank test p < 0.0001) (Fig. 3a). 
A total of 1095 (878 vs 217) composite events were 
reported with a crude event rate of 22.1 (20.7 vs 30.9) per 
1000 person-years (95% CI 20.8–23.5) (Table 1). Table 2 
shows a summary of the events for each of the individual 
MACE components with the absolute event rates.
Risk of 3‑point composite of MACE
The risk of a MACE in the unadjusted model was 53% 
(aHR: 1.53; 95% CI 1.32–1.77) higher among non-users 
compared to statin users. This was reduced slightly to 
36% (HR: 1.36; 95% CI 1.15–1.62) when we adjusted for 
age, gender, duration of insulin use, albumin, glomerular 
filtration rate, lipid profile, and coronary heart disease 
history. A similarly higher risk (89%) was observed for 
all-cause mortality (aHR: 1.89; 95% CI 1.51–2.37) among 
non-users of statins compared to statin users, but an 
opposite trend was observed for non-fatal MI and stroke: 
non-users of statins had a 12% lower risk of MI (aHR: 
Fig. 1 Selection of study participants
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0.88, 95% CI 0.35–2.23) and a 45% lower risk of stroke 
(HR: 0.55; 95% CI 0.38–0.81) (Table 2).
Subgroup and sensitivity analyses
Compared to non-users of statins, all of the individual 
statins showed higher HbA1c levels throughout the study 
(Additional file 2). The number of events for the 3-point 
composite of MACE was 398, 342, 41 and 461 among 
patients on atorvastatin, simvastatin, rosuvastatin and 
pravastatin respectively. The 5-year probability of sur-
vival differed significantly between the various statins 
(Fig. 3b; Log-rank test p < 0.0001). Table 3 shows a sum-
mary of these events, event rates and hazard ratios for 
the 3-point MACE composite and the individual com-
ponents. When compared to non-statin users, the risk 
of the composite MACE was 18% lower (aHR: 0.82; 9% 
CI 0.68–0.98) among atorvastatin users, 33% lower (aHR: 
0.67; 9% CI 0.55–0.82) among simvastatin users, 44% 
lower (aHR: 0.56; 9% CI 0.39–0.81) among rosuvastatin 
users and 22% lower (aHR: 0.78; 9% CI 0.60–1.01) among 
pravastatin users (see Additional file 2).
Finally, to test the adequacy of our multiple imputa-
tion approach in addressing the impact of some missing 
data in our dataset, we conducted a sensitivity analysis 
wherein the primary endpoints in the imputed dataset 
were compared with the dataset with missing values and 
found to be similar, thereby affirming the robustness of 
the imputation method employed. The proportional haz-
ards assumption was examined by comparing the cumu-
lative hazard plots grouped on exposure; no violations 
were observed.
Table 1 Baseline characteristics of study participants
Statin use None Total p value
(n = 10,682) (n = 2043) (n = 12,725)
Demographics
 Age (years). mean 
(SD)
59.4 (12.7) 54.3 (18.2) 58.6 (13.8) <0.001
Gender. no. (%)
 Female 5258 (49) 1122 (55) 6380 (50) <0.001
Smoking status. no (%)
 Non-smoker 5549 (52) 1137 (56) 6686 (52)
 Ex-smoker 3634 (34) 543 (27) 4177 (33) <0.001
 Current 1499 (14) 363 (18) 1862 (15)
Alcohol status. no (%)
 Never 3431 (32) 614 (30) 4045 (32)
 Ex-drinker 1133 (11) 320 (16) 1453 (11) <0.001
 Current 6118 (57) 1109 (54) 7227 (57)
Deprivation. no (%)
 Least deprived 2151 (21) 403 (21) 2554 (20)
 Second quintile 2089 (20) 382 (20) 2471 (19)
 Third quintile 2255 (22) 422 (22) 2677 (21) 0.631
 Fourth quintile 2171 (21) 399 (21) 2570 (20)
 Most deprived 1591 (16) 327 (17) 1918 (15)
Clinical parameters. mean (SD)
 HbA1c (%) 8.7 (1.8) 8.7 (2.0) 8.7 (1.8) 0.556
 BMI (kg/m2) 32.7 (6.9) 32.8 (7.2) 32.7 (6.9) 0.252
 Diabetes 
 durationa 
(years)
4.0 (4.9) 2.5 (4.3) 3.8 (4.9) <0.001
 Time on insulin 
(years)
3.7 (6.3) 2.3 (6.0) 3.5 (6.3) <0.001
 Height (m) 1.7 (0.1) 1.7 (0.1) 1.7 (0.1) 0.860
 Weight (kg) 91.4 (18.8) 91.9 (19.1) 91.5 (18.8) 0.268
 DBP (mmHg) 76.5 (10.8) 76.9 (11.1) 76.6 (10.9) 0.129
 SBP (mmHg) 136.4 (23.0) 134.6 (23.4) 136.1 (23.1) 0.002
 Albumin (g/L) 4.1 (0.4) 4.0 (0.4) 4.1 (0.4) 0.002
 ACR (mg/mol) 5.7 (8.4) 5.2 (8.5) 5.6 (8.5) 0.014
 eGFR (mLs/
min/1.73 m2)
64.6 (21.0) 68.0 (22.0) 65.1 (21.2) <0.001
 TC. (mmol/L) 4.6 (1.3) 4.7 (1.4) 4.6 (1.3) <0.001
 Triglyceride 
(mmol/L)
2.0 (1.2) 2.0 (1.2) 2.0 (1.2) 0.072
 LDL (mmol/L) 2.4 (1.1) 2.5 (1.1) 2.4 (1.1) <0.001
 HDL (mmol/L) 1.3 (0.5) 1.3 (0.5) 1.3 (0.5) 0.225
BMI categories, no. (%)
 Normal 1371 (13) 294 (14) 1665 (13)
 Overweight 2533 (24) 489 (24) 3022 (24) 0.131
 Obese 6778 (63) 1260 (62) 8038 (63)
Use of medications, no. (%)
 Aspirin 10,481 (95) 1541 (94) 12,022 (94) 0.723
 Antihyperten-
sives
9321 (87) 1217 (91) 10,538 (83) <0.001
GLTsb no (%)
 Dual Therapy 2334 (22) 904 (44) 3238 (28)
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, 
HbA1c haemoglobin A1c, HDL high-density lipoprotein, LDL low-density 
lipoprotein, TC total cholesterol, GFR glomerular filtration rate, LLT lipid lowering 
therapy, PAD peripheral arterial disease, CHD coronary heart disease, ACR 
albumin creatinine ratio, SD standard deviation
a Diabetes duration is time from first diagnosis of diabetes to date of insulin 
initiation
b GLTs (Glucose lowering therapies) denote the number of GLTs ever recorded 
for patients within the study duration and not the current regimen
Table 1 continued
Statin use None Total p value
(n = 10,682) (n = 2043) (n = 12,725)
 Triple Therapy 3400 (33) 609 (30) 4009 (33) <0.001
 More than triple 
therapy
4948 (45) 669 (26) 5478 (39)
Comorbidities, no. (%)
 Hypoglycaemia 1824 (17) 313 (15) 2137 (17) 0.052
 Heart failure 641 (6) 72 (4) 713 (6) <0.001
 PAD 756 (7) 67 (3) 823 (7) <0.001
 CHD 1390 (13) 75 (4) 1465 (12) <0.001
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Discussion
Although statins are well recognised to confer cardio-
protective benefits [1–3], there is increasing evidence of 
a link between statin use and new-onset diabetes [6–8]. 
The cardiovascular benefits usually outweigh the risk of 
developing insulin resistance [22]. More recently, sys-
tematic reviews of randomised trials and observational 
studies have shown a modest adverse effect of statin 
therapy on glycaemic control (specifically HbA1c) [10–
14]. In a meta-analysis of 9 randomised trials involving 
9696 participants with a mean follow-up of 3.6 years, the 
average HbA1c of those randomised to statin treatment 
was 0.12% (95% CI 0.04, 0.20) higher compared with 
those randomised to placebo [15]. There was also some 
Fig. 2 Mean differences in changes in HbA1c levels between the treatment groups (a) and the mean HbA1c levels in both treatment groups (b) 
(p < 0.05 from baseline for the study duration)
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heterogeneity of effect among the different statins [15]. 
However, this small effect on HbA1c may be an under-
estimate of the true effect of statins on glycaemic con-
trol in everyday practice because of the selective nature 
of patients included in RCTs, who are likely to be more 
compliant and motivated, and there may be bias in the 
data due to an unbalanced need to adjust GLTs between 
the statin and control groups. Thus, caution is needed in 
the extrapolation of RCT-derived estimates of clinical 
outcomes when formulating guidelines for routine clini-
cal practice. For ample, in a large observational cohort 
study the differences in HbA1c between statin users 
and non-users was much greater than that previously 
reported from RCTs [23].
Clinical implication
Previous observational studies and RCTs have not 
reported the effects of concomitant statin use on HbA1c 
or CV outcomes among those patients who are often at 
highest risk with established T2D and who are newly 
started on insulin therapy [23, 24]. This is an important 
and growing sub-population as primary care clinicians 
are challenged to up-titrate medication, seek better con-
trol of diabetes symptoms and HbA1c, and to judge the 
overall risks and benefits, the alternatives and the optimal 
timing of commencement of insulin therapy. Given that 
insulin-initiated patients with T2D are likely to be more 
complex, have longer disease duration and a much higher 
risk of CV disease, the present study provides important 
new information about the effects of background sta-
tin therapy on metabolic and CV outcomes in the first 
5 years after starting insulin.
Fig. 3 Kaplan-Meier curves showing the 5-year probability of survival for the 3-point composite MACE between the two treatment groups (a) and 
between the statin types (b). Log-rank test p < 0.0001 in both a and b
Table 2 Events, crude incidence rates and  hazard ratios 
of events in the two treatment groups
a Composite outcome is a three-point MACE including all-cause mortality, non-
fatal acute myocardial infarction (AMI) and non-fatal stroke
b Absolute rate at 1000 person-years
c HR (unadjusted hazard ratio)
d aHR (adjusted hazard ratio). Adjusted for age, gender, duration of insulin use, 
albumin, glomerular filtration rate, lipid profile, and coronary heart disease
Statin use (N = 10,682) None (N = 2043)
Composite  outcomea
 No of events/person-
years
878/42,484 217/7032
 Absolute  ratesb (95% CI) 20.7 (19.3–22.1) 30.9 (27.0–35.3)
 HRc (95% CI) 1 (reference) 1.53 (1.32–1.77)
 aHRd (95% CI) 1 (reference) 1.36 (1.15–1.62)
All-cause mortality
 No of events/person-
years
415/43,503 177/7098
 Absolute rates (95% CI) 9.5 (8.7–10.5) 24.9 (21.5–28.9)
 HR (95% CI) 1 (reference) 2.61 (2.19–3.12)
 aHR (95% CI) 1 (reference) 1.89 (1.51–2.37)
Acute myocardial infarction (AMI)
 No of events/person-
years
60/43,377 5/7094
 Absolute rates (95% CI) 1.4 (1.1–1.8) 0.7 (0.3–1.7)
 HR (95% CI) 1 (reference) 0.50 (0.20–1.25)
 aHR (95% CI) 1 (reference) 0.88 (0.35–2.23)
Non-fatal stroke
 No of events/person-
years
401/42,643 34/7051
 Absolute rates (95% CI) 9.4 (8.5–10.4) 4.8 (3.4–6.7)
 HR (95% CI) 1 (reference) 0.51 (0.36–0.72)
 aHR (95% CI) 1 (reference) 0.55 (0.38–0.81)
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Several conclusions can be derived from this large 
cohort study. Firstly, despite significant reductions in 
HbA1c in both groups following commencement of insu-
lin therapy, non-users of statins achieved better HbA1c 
lowering compared with statin users. There were no dif-
ferences in insulin-induced weight gain between the two 
groups but systolic BP was also lower in the non-statin 
users. It is notable in the present study that patients 
receiving statins were older, and had longer duration of 
diabetes and insulin treatment compared to non-users. 
However, the lower HbA1c reduction among statin users 
persisted even after adjusting for multiple confounders.
Secondly, compared with non-users, all of the individ-
ual statins were associated with worse HbA1c outcomes. 
This contrasts with previous RCTs which have suggested 
differential adverse effects on glycaemic control among 
the different statins [11–15]. However, in a real-world 
cohort study of insulin-treated patients, any differential 
effect of different statins on glycaemic control may have 
been offset by differences in insulin dose adjustment.
Despite achieving less of a reduction in HbA1c, statin 
users had a significantly higher probability of survival for 
the 3-point composite MACE outcome (all-cause mortal-
ity, non-fatal MI and stroke) but this finding was not rep-
licated when considering the individual risks of non-fatal 
MI or stroke. In this regard, it is worth noting that from 
RCTs the reduction in CV events is linearly related to 
LDL-cholesterol (LDL-C) reduction, especially in the first 
year of treatment, but observational studies comparing 
different statins in routine clinical practice have reported 
inconsistent outcomes depending upon the endpoints 
examined and the methods used [25–27]. Thus, discord-
ance between RCT and observational data on statins is 
not unusual, but in this study the overall ‘real life effect’ 
of statins on MACE and all-cause mortality reduction 
seems to be consistent with the established evidence 
from statin trials. However, in a similar real clinical set-
ting, unlike our in our study, moderate-intensity statin 
treatment was found to be ineffective in cardiovascular 
primary prevention for patients with diabetic nephropa-
thy [28]. This can be explained by the differences between 
these two populations, nonetheless, it provides a good 
insight as the mean eGFR our population was 66 mL s/
min/1.73 m2.
Table 3 Events, crude incidence rates and hazard ratios of events by statin types
a Composite outcome is a three-point MACE including all-cause mortality, non-fatal acute myocardial infarction (AMI) and non-fatal stroke
b Absolute rate at 1000 person-years
c HR (unadjusted hazard ratio)
d aHR (adjusted hazard ratio). Adjusted for age, gender, duration of insulin use, albumin, glomerular filtration rate, lipid profile, and coronary heart disease
None Atorvastatin Simvastatin Rosuvastatin Pravastatin
(N = 2043) (N = 4415) (N = 4462) (N = 713) (N = 1092)
Composite  outcomea
 No of events/person-years 217/7032 398/16,840 342/18,287 41/2894 97/4461
 Absolute  ratesb (95% CI) 30.9 (27.0–35.3) 23.6 (21.4–26.1) 18.7 (16.8–20.8) 14.2 (10.4–19.2) 21.7 (17.8–26.5)
 HRc (95% CI) 1 (reference) 0.75 (0.64–0.89) 0.59 (0.50–0.70) 0.45 (0.32–0.62) 0.68 (0.54–0.87)
 aHRd (95% CI) 1 (reference) 0.82 (0.68–0.98) 0.67 (0.55–0.82) 0.56 (0.39–0.81) 0.78 (0.60–1.01)
All-cause mortality
 No of events/person-years 177/7098 203/17,229 162/18,710 17/2947 33/4616
 Absolute rates (95% CI) 24.9 (21.5–28.9) 11.8 (10.3–13.5) 8.7 (7.4–10.1) 5.8 (3.6–9.3) 7.1 (5.1–10.1)
 HR (95% CI) 1 (reference) 0.45 (0.37–0.55) 0.32 (0.26–0.40) 0.22 (0.13–0.36) 0.27 (0.19–0.39)
 aHR (95% CI) 1 (reference) 0.61 (0.48–0.78) 0.49 (0.38–0.64) 0.39 (0.22–0.67) 0.39 (0.26–0.60)
Acute myocardial infarction (AMI)
 No of events/person-years 5/7094 26/17,168 21/18,670 2/2948 11/4590
 Absolute rates (95% CI) 0.7 (0.3–1.7) 1.5 (1.0–2.2) 1.1 (0.7–1.7) 0.7 (0.2–2.7) 2.4 (1.3–4.3)
 HR (95% CI) 1 (reference) 2.17 (0.83–5.65) 1.62 (0.61–4.30) 0.98 (0.19–5.03) 3.45 (1.20–9.94)
 aHR (95% CI) 1 (reference) 1.42 (0.53–3.78) 0.88 (0.32–2.40) 0.63 (0.12–3.33) 1.61 (0.54–3.78)
Non-fatal stroke
 No of events/person-years 34/7051 168/16,919 158/18,337 22/2896 53/4489
 Absolute rates (95% CI) 4.8 (3.4–6.7) 9.9 (8.5–11.6) 8.6 (7.4–10.1) 7.6 (5.0–11.5) 11.8 (9.0–15.5)
 HR (95% CI) 1 (reference) 2.07 (1.43–2.99) 1.80 (1.24–2.61) 1.59 (0.93–2.72) 2.47 (1.61–3.80)
 aHR (95% CI) 1 (reference) 1.82 (1.22–2.72) 1.67 (1.11–2.51) 1.64 (0.91–2.94) 2.42 (1.52–3.84)
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Possible underlying mechanisms
Several mechanisms have been proposed to explain how 
statins may worsen dysglycaemia: (1) impaired pancre-
atic β-cell secretion of insulin due to direct and indirect 
effects on calcium channels; (2) reduced insulin-medi-
ated glucose uptake, especially in skeletal muscle, due 
to impaired expression and/or translocation of GLUT4 
transporters from the cytosol to the plasma membrane; 
and (3) exacerbation of insulin resistance in muscle, liver 
and adipose tissues via multiple effects on insulin signal 
transduction, e.g. depletion of coenzyme Q10, inhibi-
tion of phosphorylation events downstream of the insulin 
receptor and inhibition of adipocyte differentiation [29]. 
In addition, statins have varying degrees of lipophilicity. 
The lipophilic statins diffuse passively through the hepa-
tocellular membrane to inhibit HMG-CoA reductase 
in the liver but they can also diffuse passively and easily 
into extrahepatic tissues whereas the hydrophilic statins 
require carrier-mediated transport to enter cells. This 
may explain some of the observations of a higher inci-
dence of new-onset diabetes with the lipophilic statins, 
e.g. simvastatin and atorvastatin, via effects on peripheral 
insulin sensitivity [30]. Similarly, a 6-year follow up study 
of the METSIM cohort showed that statin treatment 
increases the risk of type 2 diabetes by 46%, attribut-
able to decreases in insulin sensitivity and insulin secre-
tion [31], while simvastatin may induce insulin resistance 
through a novel fatty acid mediated cholesterol inde-
pendent mechanism [32].
Strength and limitations
Our analyses are subject to a number of limitations 
including allocation bias and residual confounders. This 
includes possible differences in compliance, indications 
for intensification of treatments, markers of β-cell dete-
rioration, frequency of hypoglycaemia and some lifestyle 
and dietary factors which could influence our findings. 
Although we could not exclude the possibility of residual 
confounders, we were able to account for differences in 
the observed covariates and used robust analytical tech-
niques to control for any confounding factors that may 
bias the results of the estimated treatment effects.
Our data were derived from a large UK database and 
therefore cannot be generalised to other ethnic groups. 
We were also unable to obtain longitudinal data on 
insulin doses, which are important in assessing insulin-
induced weight gain [33], which in turn could potentially 
influence glycaemic and CV outcomes.
On the other hand, a real strength of this study is the 
relatively large number of patients, the availability of, and 
adjustment for, a large number of known confounders, 
and the routine systematic nature of data collection in 
THIN which reflects real world practice and outcomes. 
We have also focused this study on an important patient 
population, which has not been previously studied.
Conclusions
In summary, in a large cohort of T2D patients who are 
newly started on insulin therapy, and who reflect a real-
world population in routine clinical practice, we have 
confirmed the major benefits of statin use in reducing CV 
risk and mortality. We have also quantified, for the first 
time, the modest adverse effects of background statin use 
on the HbA1c outcomes following insulin initiation. It 
is clear that, in this high-risk population, the benefits of 
statins on CV outcomes outweigh the small adverse met-
abolic effects on glycaemic control.
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